Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Tolerability of Sunvozertinib in Hepatic Impairment
NCT06084104Phase 1Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of sunvozertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Maximum observed plasma drug concentration at Day 14, Area under plasma concentration time curve from zero to infinity at Day 14 and 1 more. Started Oct 2023; status: completed.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06084104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084104.